Skip to main content

Table 1 Clinical characteristics of tumors and experiments in which corresponding xenografts were used

From: Origin of the vasculature supporting growth of primary patient tumor xenografts

Primary site description ID# Exp Sex Age Histology description Grade Path T Path N Path M AJCC stage path Treatment prior to sample
Esophagus, lower third 12944 2 M 70 Ad, NOS III 2 1 0 2B no
Esophagus, lower third 13176 2 M 40 Ad, NOS III 1 1 1 4 no
Ovary 13575 2 F 67 PSC III 3C 0 0 3C Carboplatin/Taxol
Esophagus 13618 2 nd nd nd nd nd nd nd nd nd
Ovary 13987 2 F 43 SSPC III 3C 1 0 3C no
Pleura, NOS 14967 4 M 70 Meso nd 3 0 0 3 Radiation and chemotherapy (Alimta & cisplatin)
Pancreas, head of 15010 3 F 74 Inf Duct, NOS II 3 1 0 2B no
Pancreas, body of 15406 3 M 74 Inf Duct, NOS II 2 0 0 1B no
Kidney, NOS 15773 3 M 69 RCC, NOS III 3A 0 1 4 no
Kidney, NOS 15818 3 F 57 RCC, Clear cell III 1B 0 X 1 no
Lung, upper lobe 15946 3 F 73 SCC, NOS III 2 0 0 1B no
Pancreas, tail of 16096 3 M 66 Inf Duct, NOS II 2 0 0 1B no
Colon, ascending 16115 3 M 59 Ad, NOS II X X nd nd FOLFOX with Avastin
Kidney, NOS 16616 3 M 62 RCC, NOS III 3B 0 0 3 no
Kidney, NOS 16692 2, 3 M 57 RCC, sarcomatoid IV 3B 1 X 4 no
Kidney, NOS 16803 3 M 63 RCC, Clear cell III 1A X X 1 no
Colon, ascending 16811 3 F 83 Ad, NOS II 4 0 0 2B no
Pancreas, head of 16870 3 F 31 Inf Duct, NOS III 3 1 0 2B no
Colon, Sigmoid, NOS 16879 3 F 76 Ad, NOS II 3 0 0 2A no
Pancreas, head of 17123 3 M 79 Ad, NOS III 3 1 0 2B no
Rectosigmoid junction 17224 2 F 52 Ad, NOS II 3 1 1 4 no
Lung, lower lobe 17228 3 F 82 CSC III 2 0 0 1B no
Colon, ascending 17239 2 M 71 Ad, NOS II 3 2 0 3C no
Lung, upper lobe 17246 2, 3 M 53 Ad, NOS III 3 0 0 2B no
Lung, lower lobe 17291 1, 3 F 53 Pleomorphic ca IV 3 0 nd 2B no
Tonsillar pillar 17307 2 M 67 SCC, NOS I 0 2B 1 4C no
Rectosigmoid junction 17346 3 M 57 Ad, NOS II 3 0 nd 2A no
Lung, lower lobe 17448 2, 3 M 71 Ad-SCC II 2 0 X 1B no
Colon, splenic flexure 17641 1, 2, 3 F 59 Ad, NOS II X X nd nd FOLFIRI & Avastin, Erbitux, irinotecan then oxaliplatin & Xeloda then SAHA, 5-FU and leucovorin.
Cecum 17651 3 F 74 NE n.d. 4 1 X 4 no
Rectosigmoid junction 18023 4 F 46 Ad, Mucinous II X X nd nd Avastin and FOLFOX then Xeloda and Avastin
Pancreas, overlapping lesion 18254 1, 2 F 69 Inf Duct, NOS III 3 1 X 2B no
Floor of mouth, NOS 18316 2 F 47 SCC, krt I X X nd nd Cisplatin and Taxotere
Duodenum 18484 2 M 77 Ad, NOS II 4 1 0 3 no
Pancreas, head of 18643 2 F 56 Inf Duct, NOS I 3 1 0 2B Chemoradiation: total of 5040 cGy with gemcitabine
Pancreas, overlapping lesion 19632 2 F 78 Inf Duct, NOS III 3 0 nd 2A no
Palate, soft, NOS 19785 5 M 65 SCC, lg cell, nonkrt III 0 0 X nd Induction chemotherapy
  1. For each tumor listed, the sex, age at first diagnosis, histological description, histological grade, pathological stage and treatment (if any) prior to specimen acquisition is included. The ID# refers to the de-identified number given to the procured samples. Exp indicates the experiments for which the xenograft of each tumor was used: 1- validation of antibody species-specificity, 2-localization of human mitochondria, 3- survey of time to first passage and species identification of vasculature, 4- kinetics of vascularization of engrafted tumors and 5- the perfusion study. For histological descriptions, the following abbreviations are used: NOS- not otherwise specified, Ad- adenocarcinoma, PSC- papillary serous cystadenocarcinoma, SSPC- serous surface papillary carcinoma, Meso- mesothelioma, biphasic, malignant, Inf Duct- infiltrating ductal carcinoma, RCC- renal cell carcinoma, SCC- squamous cell carcinoma, CSC- combined small cell carcinoma, Ad-Sq- adenosquamous, NE- neuroendocrine, krt- keratinizing. For histological grades the following definitions were used: Grade I: well differentiated, Grade II: moderately differentiated, moderately well differentiated, intermediate differentiated, Grade III: poorly differentiated, Grade IV: undifferentiated, anaplastic. Histological staging is per AJCC (American Joint Committee on Cancer), nd- no data.